Medimpact

## STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

### MONOMETHYL FUMARATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
MONOMETHYL	BAFIERTAM	46576		GPI-10	
FUMARATE				(6240555000)	

## **GUIDELINES FOR USE**

- 1. Does the patient have a diagnosis of a relapsing form of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The patient had a trial of or contraindication to dimethyl fumarate AND **ONE** of the following agents: Avonex, Betaseron, Copaxone/Glatiramer/Glatopa, Plegridy, Rebif, Aubagio, Vumerity, Kesimpta (**Please note:** other MS agents may also require prior authorization)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.** If no, do not approve.

**DENIAL TEXT:** \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **MONOMETHYL FUMARATE (Bafiertam)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: immune system eats away at the protective covering of the nerves), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older
- C. You have previously tried or have a contraindication to (medical reason why you cannot take) dimethyl fumarate AND ONE of the following: Avonex, Betaseron, Copaxone/Glatiramer/Glatopa, Plegridy, Rebif, Aubagio, Vumerity, Kesimpta

(Please note: Other multiple sclerosis medications may also require prior authorization)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

# CONTINUED ON NEXT PAGE

Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

## MONOMETHYL FUMARATE

### RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Bafiertam.

#### REFERENCES

• Bafiertam [Prescribing Information]. High Point, NC: Banner Life Sciences LLC; May 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Commercial Effective: 01/01/21 Created: 11/20 Client Approval: 11/20

P&T Approval: 10/20

Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.